Skillman, NJ, United States of America

Manish Gupta

This inventor holds 2 USPTO granted patents. Top assignee: Genmab A+s. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Manish Gupta. Retrieved from https://idiyas.com/inventor/manish-gupta-4pkfvwpq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Manish Gupta: Innovator in Bispecific Antibodies

Introduction

Manish Gupta is a notable inventor based in Skillman, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. His work focuses on innovative treatments for diseases, showcasing his commitment to advancing medical science.

Latest Patents

Manish Gupta holds a patent for bispecific antibodies against CD3 and CD20. This invention relates to bispecific antibodies (bsAbs) and their application in treating diseases in subjects. The patent outlines advantageous treatment regimens for B-cell Non-Hodgkin Lymphoma (B-NHL), highlighting the potential impact of his work on cancer therapies.

Career Highlights

Manish Gupta is associated with Genmab A/S, a leading biotechnology company. His role at Genmab A/S allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Some of his notable coworkers include Tahamtan Ahmadi and Tommy Li. Their collaboration fosters an environment of innovation and shared expertise, further enhancing the potential of their research.

Conclusion

Manish Gupta's contributions to the field of bispecific antibodies represent a significant advancement in medical treatments. His work not only showcases his inventive spirit but also holds promise for improving patient outcomes in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…